KNSA

$93.29+2.74%visit website

Kiniksa Pharmaceuticals International, plc

Market Cap

$14.7B

Live price × SEC shares (Oct 23, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.08

60mo monthly vs SPY

P/E (TTM)

133.8

TTM to Sep 2026 · mkt cap / net income

Flagged input, hover for details

P/S (TTM)

15.5

TTM to Sep 2026 · revenue

Flagged input, hover for details

P/B

20.6

Mkt cap / shareholders' equity

Flagged input, hover for details

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	Q3 FY2026 Sep 30, 2026	TTM Sep 30, 2026
Revenue	202,127	214,266	243,600	285,970	945,963
Cost of revenue	20,945	20,796	23,572	27,759	93,072
Research & development	34,609	27,475	40,899	32,786	135,769
Selling, general & administrative	56,775	61,151	63,866	65,361	247,153
Operating income	19,768	29,267	27,194	54,236	130,465
Pretax income	23,269	32,681	31,145	59,057	146,152
Income tax	9,070	10,089	5,713	11,712	36,584
Net income	14,199	22,592	25,432	47,345	109,568
EPS (basic) ($)		0.30	0.33	0.61	1.42
EPS (diluted) ($)		0.27	0.30	0.56	1.32
Weighted avg. shares (basic)		76,517	77,578	78,193
Weighted avg. shares (diluted)		82,410	83,398	84,920

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Oct 27, 2026, period ended Sep 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 34 more quarters, back to Jun 2017, with Tormere Pro.

Corporate Events (8-K)

1 filing in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Oct 27, 2026 accepted 7:32 AM ET	2.02Earnings release	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

26%

W/W -11.8pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

5.65x

Avg Daily Selling (90d)

7,552 sh/day

Baseline Daily Selling

3,617 sh/day

Unique Sellers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-11-03	2026-11-03	Patel Sanj K	Director & CHAIRMAN & CEO	Sale	220.2K	$93.27	$20.54M	780.0K	View
2026-11-02	2026-11-03	Moat Ross	CHIEF OPERATING OFFICER	Sale	28.0K	$92.36	$2.58M	10.3K	View
2026-11-02	2026-11-03	Ragosa Mark	CHIEF FINANCIAL OFFICER	Sale	36.8K	$92.16	$3.39M	20.9K	View
2026-11-02	2026-11-03	Patel Sanj K	Director & CHAIRMAN & CEO	Sale	89.4K	$91.86	$8.22M	869.9K	View
2026-11-02	2026-11-03	Paolini John F.	CHIEF MEDICAL OFFICER	Sale	18.4K	$93.39	$1.72M	69.9K	View

1–5 of 88

1 / 18

Recent News

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock: Insider Sanj Patel Sells 220,170 Shares

MarketBeat · 2026-11-04

A CEO exercises options at $8.83 as his trust sells Kiniksa (KNSA) shares.

Stock Titan · 2026-11-04

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock: Insider Ross Moat Sells 27,977 Shares

MarketBeat · 2026-11-04

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock: Insider John Paolini Sells 18,413 Shares

MarketBeat · 2026-11-04

Under a trading plan, Kiniksa (KNSA) medical chief exercises options and sells 96,000 shares.

Stock Titan · 2026-11-03

Under a preset trading plan, Kiniksa (KNSA) officer sells 36,260 shares.

Stock Titan · 2026-11-03

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Clears the Minervini Trend Template but Awaits a Lower-Risk Entry

ChartMill · 2026-11-03

KNSA Nov 2026 70.000 put (KNSA261120P00070000) stock price, news, quote and history

Yahoo Finance UK · 2026-11-02

JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122

Benzinga · 2026-10-30

Stock Market: Google, Amazon, Intel, ServiceNow Trigger Tech Wreck, But Other Sectors Solid: Weekly Review

Yahoo · 2026-10-30

Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101

Benzinga · 2026-10-28

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102

Benzinga · 2026-10-28

Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110

Benzinga · 2026-10-28

Kiniksa (KNSA) Stock Jumps As Q3 Results Fuel Growth Debate

Yahoo · 2026-10-28

Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors

Yahoo · 2026-10-27

Informational purposes only, not investment advice.

KNSA

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

Kiniksa Pharmaceuticals International, plc (KNSA)

Reporting Insiders

Factor Profile

Corporate Events (8-K)

Date	Insider	Type	Shares	Value
2026-11-03	Patel Sanj K	S	4,584	$432,042
2026-11-03	Patel Sanj K	S	1,214	$110,194.78
2026-11-03	Patel Sanj K	S	68,664	$6M
2026-11-03	Patel Sanj K	S	145,708	$14M
2026-11-02	Moat Ross	S	6,681	$609,507.63